
èèªèãå€§è žçã®æµžæœ€æ§è»¢ç§»ãã¿ãŒã³ãä¿é²ãç ç©¶ã§å€æ
ã«ãŒãŽã§ã³ã»ã«ããªãã¯å€§åŠïŒKU LeuvenïŒã®ç ç©¶è ãã¯ãèèªèçŸæ£ãæããå€§è žçïŒCRCïŒæ£è ã¯ãã眮æåã墿®ãã¿ãŒã³ãšããŠç¥ãããæµžæœ€æ§ã®è転移ãçºçãããªã¹ã¯ãææã«é«ããšã7æ1æ¥ä»ã® Nature ã«çºè¡šããç ç©¶ã§å ±åããããã®çºèŠã¯ãèèªçããèèªé žé žåãMYC掻æ§åããããªã³é§åã³ã©ãŒã²ã³åæã«è³ã代è¬è»žãæããã«ãããã®ã§ãããæ¢åã®è¬å€åè£ã§æšçåã§ããå¯èœæ§ãããã è転移ãçºçããCRCæ£è ã®äºåŸã¯ãè»¢ç§»å·£ãæ¡çšãã2ã€ã®ç°ãªãçµç¹ç çåŠç墿®ãã¿ãŒã³ã®ãã¡ã©ããã«ãã£ãŠå€§ããå·Šå³ããããã眮æåã転移ïŒè «ç现èãåšå²ã®èå®è³ªã«æµžæœ€ã眮ãæããïŒã®æ£è ã®5å¹Žå šçåçã¯44%æªæºã§ããã®ã«å¯Ÿããã被å åãïŒä»¥åã¯ãã¹ã¢ãã©ã¹ããã¯ãšåŒã°ããïŒè»¢ç§»ïŒè «çãç·ç¶çµç¹ã«ãã£ãŠéé¢ãããïŒã®æ£è ã§ã¯73%ã§ããããã®é¡èãªå·®ã«ããããããã眮æå転移ãç¹ç°çã«æšçãšããæ¿èªæžã¿æ²»çæ³ã¯ååšããªãã èèªèãšã®é¢é£ VIB-KUã«ãŒãŽã§ã³ççç©åŠã»ã³ã¿ãŒã®Sarah-Maria FendtãçããããŒã ã¯ãèèèªçïŒè现èãžã®èèªèç©ãäžè¬ã«èèªèãšããŠç¥ãããïŒãè»¢ç§»å¢æ®ãã¿ãŒã³ã«åœ±é¿ãäžããå¯èœæ§ããããã©ãããæ€èšããããšããå§ãããããŒã ã¯æªæ²»çã®CRCæ£è ãåæããèèªèã®ãªãæ£è ãšæ¯èŒããŠãèèªèãæããæ£è ã§ã¯çœ®æå転移ã®é »åºŠãææã«é«ãããšãèŠåºããã ã¡ã«ããºã çã«ã¯ãç ç©¶è ãã¯å€æ®µéçµè·¯ãéããŠãã®é¢é£æ§ã远跡ãããèèªçã¯èèã§ã®èèªé žé žåãå¢å ããããã®çµæã¢ã»ãã«CoAã¬ãã«ãäžæãããããã®äœå°ã¢ã»ãã«CoAã¯ãç¹å®ã®ãªã·ã³æ®åºïŒK323ïŒã§MYCã¿ã³ãã¯è³ªã®ã¢ã»ãã«åãä¿é²ããMYCãå®å®åãããŠãã®åè§£ãé²ããå®å®åãããMYCã¯ãP5CSïŒALDH18A1ïŒããã³é¢é£é µçŽ PYCR1ãšPYCR2ãäžæ¹å¶åŸ¡ããããšã«ããããããªã³åæçµè·¯ã掻æ§åãããçæããããããªã³ã¯ã眮æå転移ã墿®ã«äŸåããIåã³ã©ãŒã²ã³ïŒCOL1A1ïŒã®ç£çãä¿é²ããã ãã®çµè·¯ã¯é£éåå¿ã§ãããåæ®µéãæ¬¡ã®æ®µéã®æ¡ä»¶ãçã¿åºããèèªèã代è¬çæãäŸçµŠãã転åå åãæŽ»æ§åããã¢ããé žä»£è¬ãåç·šæããŠã眮æåè»¢ç§»ã®æ¡å€§ã«å¿ èŠãªè¶³å Žãæ§ç¯ããã è»žãæšçãšãã ç ç©¶è ãã¯è€æ°ã®ã¢ãããŒãã§ãã®çµè·¯ã®éèŠæ§ãæ€èšŒãããæ£è ç±æ¥ãªã«ã¬ãã€ãããã³ããŠã¹ç°çš®ç§»æ€ã¢ãã«ã«ãããŠãååç©MYCi975ã«ããMYCã®è¬çåŠçé»å®³ã¯ã被å å転移ã«ã¯åœ±é¿ãäžããã«çœ®æå転移ã®å¢æ®ãéžæçã«æå¶ãããP5CSãŸãã¯COL1A1ã®ããã¯ããŠã³ãåæ§ã«ã眮æå転移ã®åœ¢æãšå¢æ®ãé»å®³ããã MALDI質éåæã€ã¡ãŒãžã³ã°ãçšãã空éã¡ã¿ãããã¯ã¹ã«ãããæ£è çµç¹ãµã³ãã«äžã®çœ®æå転移ã«ã¯ã被å åè»¢ç§»ãšæ¯èŒããŠãããªã³ãã³ã©ãŒã²ã³ãMYCãP5CSã¬ãã«ãäžæããŠããããšã確èªããããããã¯åäžçµè·¯ãããã®çŸæ£ã§ãæ©èœããŠãã蚌æ ã§ããã èšåºçæçŸ© èèªçãšå€§è žçããšãã«äžè¬çãªçŸæ£ã§ããããšããããã®çºèŠã¯æ³šç®ã«å€ãããéã¢ã«ã³ãŒã«æ§èèªèçŸæ£ã¯ãè¥æºããã³ã¡ã¿ããªãã¯ã·ã³ãããŒã ã®å¢å ã«äŒŽããäžçã®æäººäººå£ã®çŽ25ã30%ã眹æ£ããŠãããšæšå®ããããCRCã¯äžçã§3çªç®ã«å€ã蚺æãããçã§ãããèèã¯æãé »åºŠã®é«ãé é転移éšäœã§ããã MYCããã®çµè·¯ã®äžå¿çããŒããšããŠåå®ãããããšã¯ç¹ã«éèŠã§ãããMYCã¯çŽæ¥çãªè¬å€æšçåãéåžžã«å°é£ã§ããããšãç¥ãããŠããããã§ãããããããP5CSãCOL1A1ãšãã£ãããåŸæ¥åã®è¬å€æšçã§ããäžæµé µçŽ ã®é¢äžã¯ã代æ¿çµè·¯ãæäŸããå¯èœæ§ããããããŒã ã¯ãŸããMYCé»å®³å€MYCi975ãåèšåºéçºæ®µéã«ãããMYCé»å®³å€OMO-103ïŒNCT04808362ïŒã®ç¬¬Içžèšåºè©Šéšãããã§ã®MYCæšçåã®æŠå¿µå®èšŒã確ç«ããããšã«ãèšåããŠããã éç æ¬ç ç©¶ã®äž»èŠãªã¡ã«ããºã ç蚌æ ã¯ãããŠã¹ã¢ãã«ããã³æ£è ç±æ¥ãªã«ã¬ãã€ãããã®ãã®ã§ãããååãèšåºè©Šéšããã®ãã®ã§ã¯ãªããæ£è ããŒã¿ã¯æšªæçãã€çžé¢çãªãã®ã§ãããèèªçã¯ããå€ãã®çœ®æå転移ãšé¢é£ããŠããããããã«ãããçŽæ¥çãªå æé¢ä¿ã¯èšŒæãããŠããªããMYCi975ã®ããŒã¿ã¯ããŠã¹ç±æ¥ã§ããããã®ååç©ãããæ£è ã§åæ§ã®éžææ§ã瀺ããã©ããã¯ä»åŸã®æ€èšŒãå¿ èŠã§ããã ããã«ãæ¬ç ç©¶ã¯CRCè転移ã®ã¿ã察象ãšãããåãèèªè-転移軞ãèèã«è»¢ç§»ããä»ççš®ïŒèµèçãä¹³çãèºçãªã©ïŒã§ãæ©èœãããã©ããã¯æªè§£æã®èª²é¡ã§ããã é瀺ïŒ2026幎7æ1æ¥ä»ã§Natureã«æ²èŒãããæ»èªä»ãè«æã«åºã¥ããDOI: 10.1038/s41586-026-10686-2ãäžåžèè S.-M. Fendtã¯BlackBelt TherapeuticsãAuron TherapeuticsãAlesta Therapeuticsããã®è³éæäŸããªãã³ã«AlestaãFund+ãDroia Venturesã«ãããé¡§å圹å²ãå ±åããŠããã é å èš³










